Zymeworks Inc (ZYME) NPV
$0.56
(4.12%)
- Add to watchlist
- This stock can be held in a
$0.56
(4.12%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.56
(4.12%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
Contact details
Important dates
General stock information
- Short code:
- ZYME
- ISIN:
- US98985Y1082
- Market cap:
- $877.50 million
- Shares in issue:
- 69.45 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- NASDAQ Comb. Composite
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.